Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2018

View Archived Issues

RNAi-mediated beta-catenin inhibition increases response rates to cancer immunotherapy in mice

Noncoding DNA affects heart risk via noncoding RNA

Considering neighborhood improves neoantigen prediction

Loxo Oncology initiates phase I/II trial of LOXO-305 in CLL/SLL and NHL

Gritstone Oncology begins phase I/II study of personalized neoantigen cancer vaccine in solid tumors

Aravive initiates phase I/II study of AVB-S6-500 in platinum-resistant recurrent ovarian cancer

Novel 7-gene expression signature accurately predicts breast cancer outcome

Enrollment opens in two studies of Xhance

Interim phase II results presented for BP-1001 in AML

High synaptojanin 2 expression predicts poor prognosis in ER-positive breast cancer

Long noncoding RNA LINC02273 regulates oncogenic gene expression and breast cancer metastasis

ME1 is a prognostic marker and potential therapeutic target in breast cancer

High periostin levels predict shorter survival in primary, nonmetastatic breast cancer

Liver injury regeneration strategy bypasses fibrosis

Alligator Bioscience initiates first-in-human study of ATOR-1015

Aplidin approved in Australia for the treatment of multiple myeloma

Positive second cohort data from phase I study of Oraxol plus ramucirumab in gastric cancer

MyoKardia reports phase Ib data for MYK-491

Lilly identifies new calcitonin gene-related peptide receptor antagonists

New adrenomedullin-2 antagonists synthesized at the University of Sheffield

Novan reports fourth cohort data from phase II trial of SB-206 for molluscum contagiosum

FDA approves Tolsura for systemic fungal infections

Noxopharm advances DARRT-1 study of Veyonda in late-stage prostate cancer

Arcus Biosciences patents adenosine receptor A2A and/or A2B antagonists

RIP-1 inhibitors discovered at Denali Therapeutics

University of Michigan divulges lysine-specific histone demethylase 1A inhibitors

Vect-Horus enters research collaboration agreement with Janssen

Aeglea announces phase III plans for pegzilarginase in arginase 1 deficiency

FDA accepts IND for Sermonix's phase II trial of oral lasofoxifene in breast cancer

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...